Form 4: Amphastar Pharmaceuticals Executive Exercises Options and Sells Shares

A recent SEC filing reveals that a senior executive at Amphastar Pharmaceuticals exercised stock options and sold shares on December 12th and 13th, 2024.

Summary

• Rong Zhou, a Senior Executive Vice President at Amphastar Pharmaceuticals, engaged in transactions involving the company's stock.
• On December 12, 2024, Zhou exercised options to acquire 7,000 shares at $11.33 per share and then sold the same 7,000 shares at $44.425 per share.
• On December 13, 2024, Zhou exercised options to acquire 8,000 shares at $11.33 per share and then sold the same 8,000 shares at $45.23 per share.
• Following these transactions, Zhou directly owns 118,469 shares and indirectly owns 99,668 shares through a family trust and 5,000 shares through their spouse.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative for the company's overall outlook.

Industry Context

This is a routine filing related to executive stock option exercises and sales, which is common in publicly traded companies. It does not indicate any specific trend or event within the pharmaceutical industry.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice in publicly traded companies, including those in the pharmaceutical sector.
• The timing and volume of these transactions are often influenced by vesting schedules and personal financial planning.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Pfizer also regularly report similar transactions by their executives.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the increased volume of shares being traded.
• The transactions do not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Amphastar Pharmaceuticals, stock options, insider trading, SEC Form 4, executive compensation, share transactions